Clinical Trial

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-06-10; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-02
Trial Details
NCT Number NCT03984565
Lead Sponsor Staci Gruber, Ph.D.
Collaborators: Etheridge Foundation
Conditions Chronic Pain
Enrollment 25 participants
Start Date 2024-06-27
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-30